Precision Medicine and Sickle Cell Disease.

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) exhibits highly variable clinical outcomes, impacting patients from childhood to old age.
• Current precision medicine applications in SCD are constrained by challenges in prognostic group identification and a limited therapeutic arsenal.
• The primary genetic determinant, β-globin genotype (HbSS vs. HbSC), influences outcomes but treatment strategies remain largely uniform.

Purpose of the Study:

• To explore the potential and limitations of precision medicine in managing sickle cell disease.
• To highlight the need for improved prognostic stratification and tailored treatment approaches in SCD.
• To discuss emerging therapies and their implications for personalized SCD care.

Main Methods:

• Review of existing literature on SCD genetics, clinical variability, and treatment strategies.
• Analysis of the impact of β-globin genotype and other genetic factors (α-thalassemia, HbF) on SCD prognosis.
• Evaluation of current and novel therapeutic agents (penicillin, hydroxyurea, crizanlizumab, voxelotor) in the context of precision medicine.

Main Results:

• Significant variability in SCD clinical outcomes necessitates personalized treatment strategies.
• Existing treatments like penicillin and hydroxyurea are broadly recommended, limiting precision.
• Emerging drugs and understanding of erythropoiesis offer future avenues for targeted SCD therapies.
• Selective blood transfusions for stroke prevention exemplify current precision medicine in SCD.

Conclusions:

• Precision medicine in SCD is hampered by difficulties in identifying distinct patient subgroups and a lack of tailored treatments.
• Further research into SCD pathology, particularly erythropoiesis, is essential for advancing personalized therapeutic approaches.
• Genomic information and novel drugS offer promise for future precision medicine strategies in sickle cell disease management.